Fragility Is Built Into the Molecule
mRNA is not a robust molecule. It was never designed to be. In a living cell, mRNA is translated quickly and then degraded, making way for new instructions. A half-life of minutes is a feature of cellular biology, not a bug.
As a pharmaceutical drug substance, that biological instability is a serious development problem. Every formulation decision you make, every excipient you select, every storage condition you define, has to work against a molecule that nature built to fall apart.
The good news is that the tools to manage it are well established. The bad news is that getting them wrong is extremely easy, and the consequences, degraded mRNA, lost potency, failed stability studies, tend to surface at the worst possible moment.
The Three Degradation Pathways That Matter
Hydrolysis
The phosphodiester backbone of RNA is susceptible to hydrolysis. Water attacks the 2-prime hydroxyl group of the ribose ring and cleaves the backbone, producing shorter RNA fragments. This reaction is accelerated by heat and by metal ions, particularly magnesium, which are present in many buffer systems.
This is why mRNA formulations use metal chelators such as EDTA to sequester trace metal ions. It is also why formulation pH matters. Hydrolysis rate is lower at slightly acidic pH; alkaline conditions accelerate degradation. Most mRNA formulations target a pH between 6.5 and 7.5 for this reason.
Ribonuclease Degradation
RNases are ubiquitous. They are on surfaces, in reagents, on gloves, in the air. A single RNase molecule can degrade thousands of mRNA molecules in seconds. mRNA formulation and manufacturing must be conducted in an RNase-controlled environment with validated procedures for equipment decontamination and reagent preparation.
The LNP formulation itself provides significant protection against RNase degradation: encapsulated mRNA is inaccessible to the enzyme. But any free mRNA in the formulation, unencapsulated drug substance that has not been removed during formulation or buffer exchange, remains vulnerable.
Physical Degradation
mRNA is a large, negatively charged polymer. It is vulnerable to aggregation, fragmentation under shear, and adsorption to surfaces. Freeze-thaw cycling can cause mRNA fragmentation if the process is not controlled. Repeated agitation during shipping can similarly degrade both the mRNA and the LNP that carries it.
The Formulation Arsenal Against Degradation
| Degradation Threat | Formulation Counter-Strategy | Critical Parameter |
| Hydrolytic backbone cleavage | Buffer at pH 6.5-7.5; EDTA as metal chelator; minimise free water activity | pH and buffer species; EDTA concentration |
| RNase contamination | RNase-controlled manufacturing environment; encapsulation within LNP; validated cleaning | Encapsulation efficiency; environmental monitoring for RNase activity |
| Thermal degradation | Frozen storage at minus 20 or minus 80 degrees C; validated cold chain; minimal freeze-thaw cycles | Storage temperature; freeze-thaw validation; shipping qualification |
| Shear-induced fragmentation | Controlled mixing during formulation; validated fill-finish parameters; avoid high-shear pumping | Mixing speed and duration; fill-finish pump type and speed |
| Oxidation | Purge headspace with nitrogen; antioxidants where compatible; limit light exposure | Nitrogen overlay; vial headspace composition |
Measuring Stability: What the Tests Actually Tell You
mRNA integrity is most commonly assessed by gel electrophoresis or capillary electrophoresis. A single sharp band at the expected size indicates intact, full-length mRNA. Smearing or lower molecular weight bands indicate degradation. The test is sensitive but semi-quantitative; small amounts of degradation can be missed.
Potency by in vitro translation assay is the functional complement. Intact mRNA produces protein; degraded mRNA does not. A product that shows apparent integrity by gel but reduced potency by translation assay has a problem that the gel alone would not have detected.
Both tests are required for GMP release of mRNA drug products under current FDA and EMA expectations. ICH Q2(R2) on analytical validation applies to the translation assay, and method development must demonstrate adequate sensitivity to detect potency losses that are clinically relevant.
The Cold Chain Question That Every Sponsor Faces
Current approved mRNA LNP products require storage at minus 20 or minus 80 degrees Celsius. That cold chain dependency limits access in lower-resource settings and adds significant cost and complexity to global clinical supply.
Lyophilised mRNA LNP formulations offer a route to improved thermostability, with some programmes targeting ambient or refrigerated storage for the freeze-dried product. The cryoprotectant system, typically sucrose or trehalose, must protect both the mRNA and the LNP structure during lyophilisation and on reconstitution. This is an active area of formulation research, and the regulatory pathway for lyophilised mRNA LNP products is still maturing.
Ardena’s mRNA Stability Expertise at Oss
Ardena’s formulation team at Oss develops and executes stability programmes for mRNA LNP products, including mRNA integrity and potency testing alongside physicochemical CQA monitoring. The site has minus 20 and minus 80 degree Celsius stability storage, and the team has experience designing stability protocols that satisfy both FDA and EMA expectations for mRNA drug substance and drug product.
